CoChat

Saturation genome editing of BAP1 functionally classifies somatic and germline variants

Open access
Waters, Andrew J., Brendler-Spaeth, Timothy, Smith, Danielle, Offord, Victoria, Tan, Hong Kee, Zhao, Yajie, Obolenski, Sofia, Nielsen, Maartje, van Doorn, Remco, Murphy, Jo-Ellen, Gupta, Prashant, Rowlands, Charlie F., Hanson, Helen, Delage, Erwan, Thomas, Mark, Radford, Elizabeth J., Gerety, Sebastian S., Turnbull, Clare, Perry, John R. B., Hurles, Matthew E., Adams, David J. · 2024 · Nature Genetics
Cited by 57

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Many variants that we inherit from our parents or acquire de novo or somatically are rare, limiting the precision with which we can associate them with disease. We performed exhaustive saturation genome editing (SGE) of BAP1, the disruption of which is linked to tumorigenesis and altered neurodevelopment. We experimentally characterized 18,108 unique variants, of which 6,196 were found to have abnormal functions, and then used these data to evaluate phenotypic associations in the UK Biobank. We also characterized variants in a large population-ascertained tumor collection, in cancer pedigrees and ClinVar, and explored the behavior of cancer-associated variants compared to that of variants linked to neurodevelopmental phenotypes. Our analyses demonstrated that disruptive germline BAP1 variants were significantly associated with higher circulating levels of the mitogen IGF-1, suggesting a possible pathological mechanism and therapeutic target. Furthermore, we built a variant classifier with >98% sensitivity and specificity and quantify evidence strengths to aid precision variant interpretation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-024-01799-3

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 38

  1. Star, P. et al. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur. J. Cancer 92, 48–53 (2018). · DOI
  2. Chau, C. et al. Families with BAP1-tumor predisposition syndrome in the Netherlands: path to identification and a proposal for genetic screening guidelines. Cancers 11, 1114 (2019). · DOI
  3. Lalloo, F. et al. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur. J. Hum. Genet. 31, 1261–1269 (2023). · DOI
  4. Fennell, D. A. et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir. Med. 9, 593–600 (2021). · DOI
  5. Pandey, G. K. et al. Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell Rep. Med. 4, 100915 (2023). · DOI
  6. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
  7. Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013). · DOI · Paper page
  8. Küry, S. et al. Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder. Am. J. Hum. Genet. 109, 361–372 (2022). · DOI
  9. Alexander, J., Findlay, G. M., Kircher, M. & Shendure, J. Concurrent genome and epigenome editing by CRISPR-mediated sequence replacement. BMC Biol. 17, 90 (2019). · DOI
  10. Barbon, L. et al. Variant Library Annotation Tool (VaLiAnT): an oligonucleotide library design and annotation tool for saturation genome editing and other deep mutational scanning experiments. Bioinformatics 38, 892–899 (2022). · DOI
  11. Radford, E. J. et al. Saturation genome editing of DDX3X clarifies pathogenicity of germline and somatic variation. Nat. Commun. 14, 7702 (2023).
  12. Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814 (2003). · DOI · Paper page
  13. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010). · DOI · Paper page
  14. Brnich, S. E. et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med. 12, 3 (2019).
  15. O’Shea, S. J. et al. A population-based analysis of germline BAP1 mutations in melanoma. Hum. Mol. Genet. 26, 717–728 (2017).
  16. Walpole, S. et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J. Natl Cancer Inst. 110, 1328–1341 (2018). · DOI · Paper page
  17. Backman, J. D. et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628–634 (2021). · DOI · Paper page
  18. Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204–220.e15 (2017). · DOI · Paper page
  19. Tung, N. et al. Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing. NPJ Precis. Oncol. 7, 76 (2023).
  20. Nishikawa, H. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 69, 111–119 (2009). · DOI · Paper page
  21. Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol. Cell. Biol. 29, 2181–2192 (2009). · DOI · Paper page
  22. Yu, H. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol. Cell. Biol. 30, 5071–5085 (2010). · DOI · Paper page
  23. Eletr, Z. M. & Wilkinson, K. D. An emerging model for BAP1’s role in regulating cell cycle progression. Cell Biochem. Biophys. 60, 3–11 (2011). · DOI · Paper page
  24. Affar, E. B. & Carbone, M. BAP1 regulates different mechanisms of cell death. Cell Death Dis. 9, 1151 (2018). · DOI · Paper page
  25. Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018–1021 (2011). · DOI · Paper page
  26. Niersch, J. et al. A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis. iScience 24, 102173 (2021). · DOI
  27. Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535–548.e24 (2019). · DOI · Paper page
  28. Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518 (2004). · DOI · Paper page
  29. Knuppel, A. et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK Biobank. Cancer Res. 80, 4014–4021 (2020). · DOI · Paper page
  30. Riikonen, R. Insulin-like growth factors in the pathogenesis of neurological diseases in children. Int. J. Mol. Sci. 18, 2056 (2017). · DOI
  31. Hellström, A. et al. Role of insulinlike growth factor 1 in fetal development and in the early postnatal life of premature infants. Am. J. Perinatol. 33, 1067–1071 (2016). · DOI
  32. Vahdatpour, C., Dyer, A. H. & Tropea, D. Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. Front. Neurosci. 10, 450 (2016). · DOI · Paper page
  33. de los Robinson-Agramonte, M. A. et al. BDNF, proBDNF and IGF-1 serum levels in naïve and medicated subjects with autism. Sci. Rep. 12, 13768 (2022).
  34. Carson, M. J., Behringer, R. R., Brinster, R. L. & McMorris, F. A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10, 729–740 (1993). · DOI · Paper page
  35. Khanbabaei, M. et al. Precocious myelination in a mouse model of autism. Transl. Psychiatry 9, 251 (2019). · DOI
  36. Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011). · DOI · Paper page
  37. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011). · DOI · Paper page
  38. Lee, C. H., Cook, S., Lee, J. S. & Han, B. Comparison of two meta-analysis methods: inverse-variance-weighted average and weighted sum of z-scores. Genomics Inform. 14, 173–180 (2016). · DOI · Paper page

Cited by

See all 57

Metadata

Authors
Waters, A. J., Brendler-Spaeth, T., Smith, D., Offord, V., Tan, H. K., Zhao, Y., Obolenski, S., Nielsen, M., van Doorn, R., Murphy, J.-E., Gupta, P., Rowlands, C. F., Hanson, H., Delage, E., Thomas, M., Radford, E. J., Gerety, S. S., Turnbull, C., Perry, J. R. B., Hurles, M. E., & Adams, D. J.
Venue
Nature Genetics
Published
2024-07
Volume
56
Issue
7
Pages
1434-1445
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W4400362311
Cited by
57
References
27
FWCI
13.79
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Wellcome Trust (220540/Z/20/A)
  • Cancer Research UK (EDDPGM-Nov22/100004)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Saturation genome editing of BAP1 functionally classifies somatic and germline variants. https://app.cochat.ai/papers/10.1038/s41588-024-01799-3
The paper
Waters, A. J., Brendler-Spaeth, T., Smith, D., Offord, V., Tan, H. K., Zhao, Y., Obolenski, S., Nielsen, M., van Doorn, R., Murphy, J.-E., Gupta, P., Rowlands, C. F., Hanson, H., Delage, E., Thomas, M., Radford, E. J., Gerety, S. S., Turnbull, C., Perry, J. R. B., . . . Adams, D. J. (2024). Saturation genome editing of BAP1 functionally classifies somatic and germline variants. Nature Genetics. https://doi.org/10.1038/s41588-024-01799-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.